Yong Ben
Chief Med & Dev Officer · BridgeBio Oncology Therapeutics, Inc.
- 2025
- Oct 5, 2026
- 7
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Yong Ben files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Yuval Cohen - $751K in CRBP purchases and sales in the last 12 months
- Sean F. Moran - $378K in CRBP purchases and sales in the last 12 months
- Nishant C. Saxena - $126K in CRBP purchases and sales in the last 12 months
- Dominic Smethurst - $77K in CRBP purchases and sales in the last 12 months
- Anne Altmeyer - $41K in CRBP purchases and sales in the last 12 months
- John Kenneth Jenkins - $38K in CRBP purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Yong Ben?
Yong Ben is a corporate insider, tracked as Chief Med & Dev Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Yong Ben submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Yong Ben been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($16K) across all tracked filings.
